title: [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To analyze the prevalence of Epstein Barr Virus (EBV) in patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  We retrospectively analyzed the clinical characteristics of 720 patients received allo-HSCT from January 2010 through December 2011 in the Stem Cell Transplant Center of People's Hospital.
  
  
  RESULTS
  Of 720 patients (469 male presented and 251 females), with a median age of 30 years (range, 2 to 67 years) old, 66 patients were presented with EBV reactivation. The cumulative incidence of EBV reactivation was (9.3±1.1)%, with a median days of 54.5 (range, 18 to 253 days). During one- year post-transplantation, the cumulative incidences of EBV reactivation in sibling allo-HSCT, haploidentical HSCT and unrelated donor HSCT were (1.3±0.7)%, (13.7±1.7)%, and (9.1±4.4)%, respectively. In patients with haplo-identical HSCT, the cumulative incidences of EBV viremia, probable EBV disease, and post-transplant lymphoproliferative disease (PTLD) were (5.8±1.1)%, (5.7±1.1)%, and (2.3±0.7)%. The mortality was (33.9±5.9)% in all patients with EBV infection: (63.6±15.8)% in PTLD, (42.3±9.9)% in probable EBV disease, (13.8±6.5)% in EBV viremia. By univariate and multivariate analysis, the use of ATG was an independent risk factor for EBV infection.
  
  
  CONCLUSIONS
  EBV reactivation is a common complication in patients with allo- HSCT, especially high mortality in PTLD and probable EBV disease. The use of ATG was an independent risk factor for EBV infection.
authors: Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
authors: Ting-ting
authors: TT
authors: Han
authors: Lan-ping
authors: LP
authors: Xu
authors: Dai-hong
authors: DH
authors: Liu
authors: Kai-yan
authors: KY
authors: Liu
authors: Xiao-hui
authors: XH
authors: Zhang
authors: Huan
authors: H
authors: Chen
authors: Yu-hong
authors: YH
authors: Chen
authors: Wei
authors: W
authors: Han
authors: Feng-rong
authors: FR
authors: Wang
authors: Yu
authors: Y
authors: Wang
authors: Jing-zhi
authors: JZ
authors: Wang
authors: Xiao-jun
authors: XJ
authors: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000473:pathology*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D004854:Herpesvirus 4, Human; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000821:virology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous; D014775:Virus Activation; D055815:Young Adult